Your browser doesn't support javascript.
loading
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Dafflon, Caroline; Gaulis, Swann; Barys, Louise; Kapur, Karen; Cornacchione, Vanessa; Schukur, Lina; Bergling, Sebastian; Traggiai, Elisabetta; Jansky, Selina; Hellmann, Leon; Engstler, Barbara Schacher; Kerr, Grainne; de Weck, Antoine; Ruddy, David A; Naumann, Ulrike; Stauffer, Frédéric; Gaul, Christoph; Lin, Ying; Billy, Eric; Weiss, Andreas; Hofmann, Francesco; Ito, Moriko; Tiedt, Ralph.
Afiliação
  • Dafflon C; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Gaulis S; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Barys L; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Kapur K; NIBR Informatics, Basel, Switzerland.
  • Cornacchione V; NIBR Biologics, Basel, Switzerland.
  • Schukur L; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Bergling S; NIBR Chemical Biology and Therapeutics, Basel, Switzerland.
  • Traggiai E; NIBR Biologics, Basel, Switzerland.
  • Jansky S; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Hellmann L; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Engstler BS; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Kerr G; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • de Weck A; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Ruddy DA; NIBR Oncology, Cambridge, MA, USA.
  • Naumann U; NIBR Analytical Sciences and Imaging, Basel, Switzerland.
  • Stauffer F; NIBR Global Discovery Chemistry, Basel, Switzerland.
  • Gaul C; NIBR Global Discovery Chemistry, Basel, Switzerland.
  • Lin Y; China Novartis Institutes for BioMedical Research, Shanghai, China.
  • Billy E; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Weiss A; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Hofmann F; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Ito M; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
  • Tiedt R; Novartis Institutes for BioMedical Research (NIBR) Oncology, Basel, Switzerland.
Oncotarget ; 11(11): 956-968, 2020 Mar 17.
Article em En | MEDLINE | ID: mdl-32215184
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suíça País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suíça País de publicação: Estados Unidos